entertainment -WSS

entertainment

author：explore 2025-10-01 12:11:20 - browse：87

Layoff concept illustration of empty desks and people walking away. — Adobe

Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular condensates, laid off 15% of its staff on Tuesday and acknowledged that a pair of collaboration deals with pharma companies had fallen apart.

The downsizing is temporary, CEO Ameet Nathwani told STAT. The company needed to hire new employees with expertise to help move the company’s first drugs into clinical trials and expand its AI capabilities. And with funding for early-stage biotechs still sparse, leadership opted to cut some positions and use the savings to fill new ones over the coming months. Roughly 20 positions were cut.

“We talked to investors right now [about raising more money], and they think that the environment for a preclinical company — it’s not even worth having that discussion,” Nathwani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

WSS

Virtual Event: March of the Biosimilars

Nurses recount patients attacks

U.K. researchers warn about biases in medical devices, algorithms

Leading voice in opioid treatment defends methadone clinic system

Crowdfunding for unproven stem cell procedures spreads misinformation

The biotech scorecard for Q3: 15 stock

hotspot

entertainment

focus

Virginia high school admissions case could be legal follow

Drug cartel violence flares in western Mexico after vigilante leader's killing

In Memoriam: Notable people who died in 2023

Colonoscopy prep: Liquid

23andMe had bad news about my health. I wish a person had delivered it

Intermittent fasting comes with a heart risk? Not so fast

Alkermes shareholders re

AstraZeneca lung cancer study comes in below expectations

Trump demands the U.S. pay no more for drugs than other countries … again

U.K. researchers warn about biases in medical devices, algorithms

focus

Use doctors trained outside the U.S. to ease the physician shortage

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

UnitedHealth increases loan offers after Change Healthcare outage

UnitedHealth increases loan offers after Change Healthcare outage

Methadone treatment changes are coming. Do they go far enough?

Vertex cell therapy lets patients with type 1 diabetes stop insulin

hotspot

hotspot

hotspot

hotspot